Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS) and Provides Progress Update on COVID-19 antibody tests
12 août 2020 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Biomerica’s...
Biomerica Announces Filing of New Three Year Shelf Registration Statement
22 juil. 2020 06h39 HE
|
Biomerica, Inc.
IRVINE, Calif., July 22, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has filed a new three year shelf registration statement on Form S-3 with the United States...
The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial
29 juin 2020 21h39 HE
|
Biomerica, Inc.
InFoods® Diagnostic-Guided Therapy is designed to identify patient-specific foods that, when removed from the diet, may alleviate an individual's IBS symptoms Approximately 45 million Americans...
Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19
16 juin 2020 08h19 HE
|
Biomerica, Inc.
This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA. This test adds to the previously announced...
Mayo Clinic joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial
01 juin 2020 07h38 HE
|
Biomerica, Inc.
Biomerica also announces its first Japanese patent has been granted for its InFoods® IBS Diagnostic Guided Therapy technology InFoods® Diagnostic-Guided Therapy is designed to identify...
Biomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution
07 mai 2020 06h36 HE
|
Biomerica, Inc.
New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus exposure. The test can be performed anywhere by...
Biomerica Announces Third Quarter Financial Results
15 avr. 2020 08h30 HE
|
Biomerica, Inc.
IRVINE, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $3,967,712 for the nine months ending February 29, 2020, compared to $4,034,822 for the...
Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs
02 avr. 2020 07h38 HE
|
Biomerica, Inc.
Price point of this high-volume laboratory version test is expected be as low as $10 per patient Once developed and scaled-up, Biomerica’s existing production capacity could allow for over 1,000,000...
Biomerica Begins Shipping Samples of 10 Minute Test for COVID-19 Virus Exposure
17 mars 2020 20h16 HE
|
Biomerica, Inc.
10-minute test for coronavirus exposure utilizing blood from a finger prick can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor’s office Biomerica has begun...
Biomerica Announces $2.0 Million Investment by Palm Global Small Cap Master Fund
26 févr. 2020 16h41 HE
|
Biomerica, Inc.
IRVINE, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) (the “Company” or “Biomerica”) announced today that the Company completed a private placement of $2 million of...